ClinicalTrials.gg
CompletedNCT02251938SPRINGUpdated Feb 12, 2020Results posted

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program

A Phase 3 interventional study of DE-109 440 μg in Non-Infectious Uveitis of the Posterior Segment of the Eye, sponsored by Santen Inc.. Completed at 25 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.

Enrollment
32nd of 100
60 · median 19
Started
2014
with 4 others
Phase 3
31 of 139
none open now
Registered
88th of 139
by date

Among the 139 studies in Uveitis with a site in United States, this one is the 32nd largest by enrollment of the 100 interventional ones that give a count, is one of 5 that started in 2014, is one of 31 in phase 3, and was the 88th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Uveitis with a site in United States, or all of them as a file.
02

Study summary

The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA development program.

Read the detailed description

This is a multicenter, open-label, extension study of intravitreal injections of the 440 μg dose of DE-109 in subjects with non-infectious uveitis of the posterior segment who received any dose of DE-109 and exited the SAKURA program under Santen Protocol 32-007, Amendment 05.

Subjects who were randomized and received at least two injections of DE-109 during the first five months of the SAKURA program and obtained clinical benefit from the study medication, as determined by the Investigator, may be considered for entry in this 12-month extension study. The minimum time lag from last injection in the SAKURA program to entry into the current protocol is 60 days.

03

Conditions studied

  • Non-Infectious Uveitis of the Posterior Segment of the Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participated in the SAKURA study
  2. Received clinical benefit from treatment in the SAKURA study
  3. Ability to sign and attend all study visits

Exclusion criteria

Exclusion Criteria:

  1. Uveitis of infectious etiology
  2. Implanted device
  3. Suspected or confirmed central nervous system or ocular lymphoma
  4. Uncontrolled glaucoma
  5. Significant ocular disease
  6. Intravitreal injections in the past 60 days
  7. Intraocular surgery or treatment
  8. Ocular or periocular infection
  9. History of herpetic infection
  10. Toxoplasmosis or toxoplasmosis scar
  11. Ocular
  12. Vitrectomy
  13. Allergy or to study drug
  14. Participation in other uveitis device clinical trials within 30 days
  15. Any recent systemic condition/infection
  16. therapy or immunocomprimised
  17. Cytomegalovirus infection
  18. Malignancy in remission
  19. Females who are pregnant or lactating and who are not using adequate
  20. Medical marijuana or illegal drug use
  21. Systemic saroidosis
  22. Therapeutic radiation to the head or neck
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    DE-109 Sirolimus

    DE-109 440 μg

    Drug: DE-109 440 μg

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye

    Best Corrected Visual Acuity (BCVA) measures the acuteness or clearness of best-corrected vision in ETDRS (Early Treatment of Diabetic Retinopathy Study) letters. An increase in BCVA indicates improvement in the best-corrected vision. A BCVA score of 85 ETDRS letters is equivalent to 20/20 vision, which is considered normal vision.

    Time frame: Day 1 (Baseline) and Month 12 or early termination visit

  2. Mean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye

    Intraocular pressure (IOP), the fluid pressure inside the eye, was measured by applanation tonometry in millimeters mercury (mmHg) with one decimal point.

    Time frame: Day 1 (Baseline) and Month 12 or early termination visit

  3. Number of Subjects With a Shift in Choroid Status at Month 12 in the Study Eye.

    Ophthalmoscopy findings were reported as normal or abnormal.

    Time frame: Day 1 (Baseline) and Month 12 or early termination visit

  4. Changes From Baseline in Vitreous Haze (VH) Scores at Month 12

    Vitreous Haze (VH) scores were measured using the modified Standardized Uveitis Nomenclature Photographic Scale (SUN) : 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

    Time frame: Day 1 (Baseline) and Month 12 or early termination visit

  5. Number of Subjects Who Receive Rescue Therapy.

    Rescue therapy was defined as any treatment that would have a therapeutic effect on the uveitis in the posterior segment (e.g., systemic treatment with an immunosuppressant agent, or a corticosteroid injection in the study eye) other than intravitreal DE-109 determined by the Investigator.

    Time frame: By Month12

  6. Number of Subjects With a Shift in Macula Status at Month 12 in the Study Eye.

    Ophthalmoscopy findings were reported as normal or abnormal.

    Time frame: Day 1 (Baseline) and Month 12 or early termination visit

  7. Number of Subjects With a Shift in Optic Nerve Status at Month 12 in the Study Eye.

    Ophthalmoscopy findings were reported as normal or abnormal.

    Time frame: Day 1 (Baseline) and Month 12 or early termination visit

  8. Number of Subjects With a Shift in Retina Status at Month 12 in the Study Eye.

    Ophthalmoscopy findings were reported as normal or abnormal.

    Time frame: Day 1 (Baseline) and Month 12 or early termination visit

07

Results

Posted Feb 12, 2020

Participant flow

Participant flow — Overall Study
MilestoneDE-109 440 μg
Started60
Completed43
Not completed17

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye

Best Corrected Visual Acuity (BCVA) measures the acuteness or clearness of best-corrected vision in ETDRS (Early Treatment of Diabetic Retinopathy Study) letters. An increase in BCVA indicates improvement in the best-corrected vision. A BCVA score of 85 ETDRS letters is equivalent to 20/20 vision, which is considered normal vision.

Time frame:
Day 1 (Baseline) and Month 12 or early termination visit
Reported as:
Mean · ETDRS Letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye
ETDRS LettersDE-109 440 μg
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye2.1 ± 11.35
PrimaryMean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye

Intraocular pressure (IOP), the fluid pressure inside the eye, was measured by applanation tonometry in millimeters mercury (mmHg) with one decimal point.

Time frame:
Day 1 (Baseline) and Month 12 or early termination visit
Reported as:
Mean · mmHg
Mean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye
mmHgDE-109 440 μg
Mean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye0.3 ± 4.16
PrimaryNumber of Subjects With a Shift in Choroid Status at Month 12 in the Study Eye.

Ophthalmoscopy findings were reported as normal or abnormal.

Time frame:
Day 1 (Baseline) and Month 12 or early termination visit
Reported as:
Number · Subjects
Number of Subjects With a Shift in Choroid Status at Month 12 in the Study Eye.
SubjectsDE-109 440 μg
Normal to Normal36
Normal to Abnormal0
Abnormal to Normal4
Abnormal to Abnormal3
PrimaryChanges From Baseline in Vitreous Haze (VH) Scores at Month 12

Vitreous Haze (VH) scores were measured using the modified Standardized Uveitis Nomenclature Photographic Scale (SUN) : 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

Time frame:
Day 1 (Baseline) and Month 12 or early termination visit
Reported as:
Mean · score on a scale
Changes From Baseline in Vitreous Haze (VH) Scores at Month 12
score on a scaleDE-109 440 μg
Changes From Baseline in Vitreous Haze (VH) Scores at Month 12-0.09 ± 0.847
PrimaryNumber of Subjects Who Receive Rescue Therapy.

Rescue therapy was defined as any treatment that would have a therapeutic effect on the uveitis in the posterior segment (e.g., systemic treatment with an immunosuppressant agent, or a corticosteroid injection in the study eye) other than intravitreal DE-109 determined by the Investigator.

Time frame:
By Month12
Reported as:
Count of participants · Participants
Number of Subjects Who Receive Rescue Therapy.
ParticipantsDE-109 440 μg
Number of Subjects Who Receive Rescue Therapy.9
PrimaryNumber of Subjects With a Shift in Macula Status at Month 12 in the Study Eye.

Ophthalmoscopy findings were reported as normal or abnormal.

Time frame:
Day 1 (Baseline) and Month 12 or early termination visit
Reported as:
Number · Subjects
Number of Subjects With a Shift in Macula Status at Month 12 in the Study Eye.
SubjectsDE-109 440 μg
Normal to Normal20
Normal to Abnormal2
Abnormal to Normal6
Abnormal to Abnormal15
PrimaryNumber of Subjects With a Shift in Optic Nerve Status at Month 12 in the Study Eye.

Ophthalmoscopy findings were reported as normal or abnormal.

Time frame:
Day 1 (Baseline) and Month 12 or early termination visit
Reported as:
Number · Subjects
Number of Subjects With a Shift in Optic Nerve Status at Month 12 in the Study Eye.
SubjectsDE-109 440 μg
Normal to Normal39
Normal to Abnormal2
Abnormal to Normal0
Abnormal to Abnormal2
PrimaryNumber of Subjects With a Shift in Retina Status at Month 12 in the Study Eye.

Ophthalmoscopy findings were reported as normal or abnormal.

Time frame:
Day 1 (Baseline) and Month 12 or early termination visit
Reported as:
Number · Subjects
Number of Subjects With a Shift in Retina Status at Month 12 in the Study Eye.
SubjectsDE-109 440 μg
Normal to Normal34
Normal to Abnormal2
Abnormal to Normal1
Abnormal to Abnormal6

Adverse events

Collected over An on-study Adverse Events (AEs) were collected after the date of the written informed consent until the Last Study Visit at Month 12 or early termination visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DE-109 440 μg0/60 (0%)8/60 (13.3%)35/60 (58.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventDE-109 440 μg
Intraocular Pressure IncreasedInvestigations2/60
CataractEye disorders1/60
Visual Acuity ReducedEye disorders1/60
Vitreous HemorrhageEye disorders1/60
Cerebrovascular AccidentNervous system disorders1/60
Trigeminal NeuralgiaNervous system disorders1/60
Cellulitis GangrenousInfections and infestations1/60
Procedural ComplicationInjury, poisoning and procedural complications1/60
Pathological FractureMusculoskeletal and connective tissue disorders1/60
Lung Adenocarcinoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60
Most frequent other events
Most frequent other events
EventDE-109 440 μg
UveitisEye disorders8/60
Intraocular Pressure IncreasedInvestigations7/60
Cystoid Macular OedemaEye disorders6/60
Intermediate UveiEye disorders6/60
IridocyclitisEye disorders3/60
Macular FibrosisEye disorders3/60
Intraocular Pressure DecreasedInvestigations3/60
SinusitisInfections and infestations3/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)DE-109 440 μg
Mean43.31 ± 15.092
Sex: Female, Male
Sex: Female, Male(Participants)DE-109 440 μg
Female31
Male29
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DE-109 440 μg
American Indian or Alaska Native1
Asian21
Native Hawaiian or Other Pacific Islander0
Black or African American4
White30
More than one race2
Unknown or Not Reported2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DE-109 440 μg
Hispanic or Latino10
Not Hispanic or Latino47
Not reported3
Geographic Region
Geographic Region(Participants)DE-109 440 μg
United States33
India17
Europe, the Middle East and Africa10
08

Study locations

25 sites
  • Phoenix, Arizona, United States
  • Sacramento, California, United States
  • Golden, Colorado, United States
  • Tampa, Florida, United States
  • Oak Park, Illinois 60304, United States
  • Jackson, Michigan, United States
  • Saint Louis, Missouri, United States
  • New Brunswick, New Jersey, United States
  • Palisades Park, New Jersey, United States
  • New York, New York, United States
  • Orchard Park, New York, United States
  • Austin, Texas, United States
  • Salt Lake City, Utah, United States
  • Graz, Austria
  • Paris, France
  • Hyderabad, Andhra Pradesh, India
  • Aurobindo Marg, New Dehli, India
  • Daryaganj, New Dehli, India
  • Bhubaneswar, Odisha, India
  • Chennai, Tamil Nadu, India
  • Madurai, Tamil Nadu, India
  • Noida, Uttar Pradesh, India
  • Milano, Italy
  • Ankara, Turkey
  • Izmir, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Nov 2017, 37 months.

Results were first posted in Feb 2020, 2 years 3 months after primary completion.

Of 15 phase 3 interventional studies under Uveitis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2014
First posted
Sep 29, 2014
StartActual
Sep 29, 2014
Primary completionActual
Nov 1, 2017
CompletionActual
Nov 27, 2017
Results first posted
Feb 12, 2020
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02251938
Lead sponsor
Santen Inc.
Responsible party
Sponsor
First posted
Sep 29, 2014
Start date
Sep 29, 2014
Primary completion
Nov 1, 2017
Completion
Nov 27, 2017
Results posted
Feb 12, 2020
Last update
Feb 12, 2020

Study contacts

Lanita Scott, MD
study director · Santen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion